in-lin result analyt hold surpris
post in-lin earn guidanc consensu estim
guidanc could upsid histor cyclic
peer discoveri analyt da busi surpris leav us
believ guid appear conserv
discoveri analyt da histor cyclic busi would
post low-single-digit growth current macro environ surpris
organ versu street estim da aid resumpt core
food busi strong cannabi test demand diagnost face comp
post growth compar street expect driver weak
includ continu soft appli genom autom robot equip
impact genom lab consolid
post report organ growth versu street
estim ep three-cent beat
quarter year
guidanc compar street revenu
billion compar street billion
model updat introduc quarterli estim along
estim increas revenu mn account
contribut meizheng cisbio reflect slightli favor
view da portfolio howev maintain organ growth estim
tweak opm adjust extra
week drag howev maintain ep estim
organ growth estim increas slightli
introduc organ growth estim addit rais
ep estim yoy base higher revenu
base previou commentari continu execut leverag
increas focu lean oper coupl increment contribut
euroimmun sequenc vanadi introduc ep estim
fair valu maintain neutral rate fv fv
reach appli multipl consolid ep
subtract net debt fv also reach appli
multipl ebitda subtract net debt compar
peer trade ep ebitda estim
million except per share data
amort intang
annual revenu break-out margin
revenu
revenu
